Please login to the form below

Not currently logged in
Email:
Password:

Immunomedics

This page shows the latest Immunomedics news and features for those working in and with pharma, biotech and healthcare.

Bluebird and Celgene BCMA CAR-T kicks off ASCO

Bluebird and Celgene BCMA CAR-T kicks off ASCO

Immunomedics will present phase I/II result of its Trop-2-targeting sacituzumab govitecan (IMMU-132) in breast cancer - which prompted an investor revolt when the biotech’s former management tried

Latest news

  • Seattle Genetics claims key US approval for Adcetris Seattle Genetics claims key US approval for Adcetris

    The approval is also important for Seattle after its aborted $2bn deal to license Immunomedics’ IMMU-132, another ADC drug for triple-negative breast cancer (TNBC), which was scuppered by a ... shareholder and claimed the jobs of Immunomedics’ CEO

  • Activists torpedo Immunomedics deal with Seattle Genetics Activists torpedo Immunomedics deal with Seattle Genetics

    Immunomedics shareholders - pointing out that the company has failed to bring any products to market in its 35-year history. ... Now, its would-be partner has decided to duck out of the messy business although it retains a stake in Immunomedics.

  • Seattle Genetics signs $2bn deal for Immunomedics' cancer drug Seattle Genetics signs $2bn deal for Immunomedics' cancer drug

    Immunomedics has signed up Seattle Genetics as the licensee for its triple-negative breast cancer (TNBC) drug IMMU-132, getting $300m upfront and another $1.7bn in possible milestone payments. ... Immunomedics' chief executive Cynthia Sullivan said she

  • Lupus – a 'great imitator'

    Targeting B-cell activation appears to be the chosen route for the majority of treatments for SLE, including epratuzumab (Epratucyn, Immunomedics/UCB).

  • R&D news in brief

    UCB also announced that it voluntarily suspended phase III trials of experimental treatment for lupus, epratuzumab, after a routine quality audit of the facilities of its partner, Immunomedics.

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Collaboration, licence. 310. Immunomedics/ Royalty Pharma. Royalty rights to sacituzumab govitecan (IMMU- 132) across all indications. ... metastases.  The acquisition helps to bolster Seattle's late stage pipeline and comes at a lower price tag than

  • Deal Watch March 2017 Deal Watch March 2017

    In an unusual development, the recent licensing deal between Immunomedics and Seattle Genetics, whereby Seattle Genetics is to pay $250m in cash, up to $1.7bn in milestones, and royalties, has ... The activist investor venBio, which has recently gained

  • Deal Watch February 2017 Deal Watch February 2017

    Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... Acquisition - company. 2, 475.

  • Pharma deals during October 2013 Pharma deals during October 2013

    The dispute between the parties concerns development delays that Immunomedics argued were material breach of the agreement. ... there may be potentially good prospects for Immunomedics to find another partner once the dust has settled. .

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics